Bogart’s Legacy investigates critical questions in canine health and oncology, translates complex evidence into practical understanding, advocates for informed consent and individualized care, and brings together people committed to improving veterinary treatment and safeguards.
Canine oncology still contains important questions about treatment safety, monitoring, supportive care, liver injury, and treatment decision-making that deserve rigorous investigation.
Research has little value if families cannot use it. Bogart’s Legacy turns complex veterinary evidence into clear, practical information for owners and professionals.
Families deserve an honest understanding of risks, alternatives, and treatment options. Care should reflect the individual dog rather than rely blindly on a one-size-fits-all approach.
Researchers, veterinary professionals, advocates, and committed dog owners all have a role in improving standards of care. Bogart’s Legacy exists to connect knowledge with action.
Some areas, including MDR1/ABCB1, raise breed-specific and genotype-specific questions that may affect drug sensitivity, treatment response, and supportive-care decisions. These questions belong within the broader research mission, but they should not define the organization as a whole.
Many chemotherapy drugs used in veterinary oncology were originally developed and approved for human patients and are prescribed to dogs off-label. Only a limited number of cancer drugs carry approval specifically for canine use.
That reality does not make these treatments inappropriate, but it does make clear, evidence-based guidance around dosing, monitoring, adverse effects, supportive care, and treatment modification especially important.
No two dogs respond to chemotherapy identically, and Bogart’s Legacy is not calling for rigid, one-size-fits-all treatment protocols.
What we are calling for is clearer guidance around the decisions that surround treatment: when a dose should be held or modified, when supportive care should begin, when additional monitoring is warranted, and when a serious treatment-related complication requires a change in course.
Individualized medicine should allow veterinarians to adapt treatment to the dog in front of them while still working from meaningful clinical safeguards.
Uncommon adverse events should not be treated as reasons to lower the standard of monitoring or response. Clearer thresholds for holding treatment, increasing surveillance, initiating supportive care, and responding to significant toxicity can help veterinarians and families make better decisions without eliminating appropriate clinical judgment.
That is the kind of reform Bogart’s Legacy is working toward.
A curated, categorized library of original papers, literature reviews, hypotheses, and related research designed to preserve knowledge and make it accessible.
View the library →Where evidence, documented gaps, and real-world experience are translated into proposed safeguards, stronger informed-consent practices, and more consistent standards of care.
See the case for reform →